Basic Information
| LncRNA/CircRNA Name | FALEC |
| Synonyms | FALEC, FAL1, LINC00568, ncRNA-a1 |
| Region | GRCh38_1:150515757-150518032 |
| Ensemble | ENSG00000228126 |
| Refseq | NR_051960 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | prostate cancer tissues, cell lines (WPMY-1, PC-3, DU145, 22RV-1 and LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | In a total of 85 patients, FALEC expression was significantly increased in clinical PCa tissues compared to adjacent normal tissues, and can be considered as an independent prognostic factor in patients with PCa. Downregulation of FALEC could inhibit cell proliferation, migration and invasion in vitro. In vivo tumorigenesis study and orthotopic bioluminescence image also support the evidence that FALEC may promote the progression of prostate cancer. We also find FALEC is a potential hypoxia induced lncRNA and can be induced by the hypoxia master regulator HIF-1a. A dramatically shorter BCR time of patients with high levelofFALECwereobservedwhencomparedwiththosewithlowlevel ofFALEC( P = 0.033). |
| Pubmed ID | 28585762 |
| Year | 2018 |
| Title | Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients. |
External Links
| Links for FALEC | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |